Successful rechallenge with avelumab in a patient with advanced Merkel cell carcinoma who presented pembrolizumab‐induced myositis
Abstract Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin cancer, associated with high mortality. Immune checkpoint inhibitors (ICIs) have demonstrated long‐lasting efficiency for treating advanced MCC. Despite a good safety profile, ICI remain associated with non‐negligible...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Book |
| Published: |
Wiley,
2023-12-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|